Nov 30, 2023 7:00am EST Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Nov 17, 2023 8:00am EST Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
Nov 13, 2023 8:00am EST Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
Sep 21, 2023 8:00am EDT Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Aug 11, 2023 1:00pm EDT Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
Aug 08, 2023 10:30pm EDT Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
Jul 25, 2023 1:00pm EDT Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023
Jun 26, 2023 8:00am EDT Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
May 15, 2023 8:00am EDT Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update
